A specific substrate to Mu class glutathione S-transferase (GST), 1,2-dichloro-4-nitrobenzene (DCNB), was administered to mice with a disrupted GST Mu 1 gene (Gstm1-null mice) to investigate the in vivo role of murine Gstm1 in toxicological responses to DCNB. A single oral administration of DCNB at doses of 500 and 1000 mg/kg demonstrated a marked increase in blood methemoglobin (MetHB) in Gstm1-null mice, but not in wild-type mice. Therefore, Gstm1-null mice were considered to be more predisposed to methemoglobinemia induced by a single dosing of DCNB. In contrast, 14-day repeated dose studies of DCNB at doses up to 600 mg/kg demonstrated a marked increase in blood MetHB in both wild-type and Gstm1-null mice. However, increases in the blood reticulocyte count, relative spleen weight and extramedullary hematopoiesis in the spleen were markedly observed in Gstm1-null mice compared with wild-type mice. In addition, microarray and quantitative RT-PCR analyses in the spleen showed exclusive up-regulation of hematopoiesis-related genes in Gstm1-null mice. These changes were considered to be adaptive responses to methemoglobinemia and attenuated the higher predisposition to methemoglobinemia observed in Gstm1-null mice in the single dose study.
Introduction
Glutathione S-transferases (GSTs) are major phase II conjugation enzymes that catalyze the conjugation of electrophilic compounds to glutathione (GSH). Electrophilic compounds, which are produced in the metabolic process of several chemicals, such as acetaminophen (Larson, 2007) , bromobenzene (Lau et al., 1980) and aflatoxin B1 (Guengerich et al., 1998) , covalently bind to cellular macromolecules and induce severe toxicity. Accordingly, GSTs are generally recognized as important enzymes that detoxify electrophilic compounds produced by environmental carcinogens/toxicants, pesticides and drugs (Eaton and Bammler, 1999) .
However, the contribution of each GST isoform to xenobiotic-induced toxicity has not been well elucidated. Various isoforms of GST have been identified and classified into three families in terms of cellular localization, namely, cytosolic, mitochondrial and microsomal GSTs. Cytosolic GSTs comprise the largest family and are further classified into seven classes (Alpha, Mu, Pi, Theta, Sigma, Zeta and Omega) (Hayes et al., 2005) . Furthermore, each class of GSTs is composed of several isoforms in both experimental animals and humans. When normal animal models are used, it is difficult to reveal the contribution of the isoforms which are responsible for metabolism and toxicity, especially in vivo (Gonzalez, 2003) . Among the seven isoforms (GSTM1-GSTM7) of Mu class GST, GSTM1 is highly expressed in the liver and is considered to be a crucial GST isoform in mice, rats and humans (Mitchell et al., 1997; Mannervik., 1985; Eaton and Bammler, 1999) , and species differences in substrate specificity have been reported (Hansson et al., 1999) . This article has not been copyedited and formatted. The final version may differ from this version. In general, drug metabolism is widely recognized as an important factor that determines the incidence of toxicity by xenobiotics. In the last decade, genetically modified animals have been produced and used to examine the role of drug-metabolizing enzymes in vivo. In phase I enzymes, Cyp1a1, Cyp1a2, Cyp1b1 and Cyp2e1 knockout (null) mice were produced and many studies were performed in order to examine in vivo metabolism, toxicity and carcinogenesis (Gonzalez and Kimura, 2003) . In addition, knockout mice of Cyp3a family were recently produced and applied to the generation of CYP3A4 humanized mice to predict in vivo human metabolism (van Herwaarden et al., 2007) . In phase II enzymes, toxicological approaches using knockout mice are very limited, although six lines of knockout mice for cytosolic GSTs have been established so far. Gstp1/p2 (Henderson et al., 1998) , Gsta4 (Eagle et al., 2004) , Gstm1 (Fujimoto et al., 2006) , Gstt1 (Fujimoto et al., 2007) , Gstz1 (Fernandez-Canon et al., 2002; Lim et al., 2004) and Gsto1 (Chowdhury et al., 2006 ) knockout mice have already been established and characterization of their phenotypes has been performed. Few studies, such as acetaminophen administration to GSTp1/p2 knockout mice (Elsby et al., 2003) , paraquat administration to Gsta4 knockout mice (Engle et al., 2004) and carbon tetrachloride administration to Gsta4 knockout mice (Dwivedi et al., 2006) , have been performed in order to investigate toxicological responses to xenobiotics using knockout mice for GSTs. Although these investigated compounds, such as acetaminophen, paraquat and carbon tetrachloride, were typical toxicants and provided significant information, they were not necessarily specific substrates for GST isoforms that were disrupted in each study. Accordingly, in vivo administration of specific substrates This article has not been copyedited and formatted. The final version may differ from this version. for disrupted GST isoforms would also be a useful approach to investigate the relationship between the drug metabolism mediated by GSTs and the subsequent incidence of toxicity.
Based on these backgrounds, we generated mice with disrupted Gstm1 gene (Gstm1-null mice) by gene targeting and characterized its phenotypes by in vitro and in vivo metabolic studies using 1,2-dichloro-4-nitrobenzene (DCNB) (Fujimoto et al., 2006) . As notable phenotypes, Gstm1-null mice showed markedly low GST activity to DCNB in the in vitro studies using cytosol prepared from the liver and kidney. In addition, in vivo administration of DCNB showed a high plasma concentration of DCNB in Gstm1-null mice compared with the wild-type control. From these results, DCNB was considered to be a specific substrate for murine GSTM1 and the in vivo administration of DCNB to Gstm1-null mice would provide useful information on the utilization of genetically modified animals.
In practice, we are curious as to whether higher exposure to DCNB in Gstm1-null mice causes severe toxicity. DCNB is a basic chemical for the synthesis of intermediates which are further processed to herbicides, bactericides and dyestuffs. Also, it has been registered in the Hazardous Substances Data Bank (HSDB: http://toxnet.nlm.nih.gov/cgi-bin/sis/htmlgen?HSDB), which is a database of potentially hazardous chemicals. In addition, the biological threshold limit value in human urine has been established for nitro and amino aromatics, including DCNB because it has been reported to have a potential risk of methemoglobinemia (Linch, 1974) . Regarding p-nitrochlorobenzene and nitrobenzene, chemical analogues of DCNB, it has been reported that they cause methemoglobinemia in experimental animals and humans (Watanabe et al., 1976; Schimelman et al., 1978) . In this study, we This article has not been copyedited and formatted. The final version may differ from this version. 
Materials and Methods

Generation and maintenance of Gstm1-null mice
Gstm1-null mice were generated by homologous recombination in embryonic stem cells as described previously (Fujimoto et al., 2006) . Wild-type and Gstm1-null mice were maintained in C57BL/6J and 129S1 mixed background.
Animal care
All mice described in these studies were kept in a controlled environment at a room temperature of 23 ± 2°C and humidity of 55 ± 10% with an illumination period of 12 hr (7:00 to 19:00) per day. Each mouse was housed individually in bracket cages and fed ad libitum with solid feed (Certified Rodent Diet 5002: PMI Nutrition International, Inc., Tokyo, Japan) sterilized by radiation (irradiated with a 60 Co-γ ray of 30 kGy), and tap water was supplied by an automatic watering system. The studies were approved by the Ethics Review Committee for Animal Experimentation of Sankyo Co., Ltd., and 
Study designs
Wild-type and Gstm1-null mice of males and females at 14-16 weeks of age were orally administered with DCNB (Wako Pure Chemical Industries, Ltd., Osaka, Japan) which was suspended in 0.5% methylcellulose solution. The dose levels of DCNB were 0, 500 and 1000 mg/kg in the single dose study and 0, 150, 300 and 600 mg/kg in the 14-day repeated dose study. An additional 14-day This article has not been copyedited and formatted. The final version may differ from this version. repeated dose study was conducted to perform a pathological examination. The dose levels for this pathological study were set at 0, 150 (only females) and 300 mg/kg in order to avoid mortality. The first day of administration was defined as Day 1 and autopsies were performed 24 hours after the last dosing in each study.
Study designs of toxicokinetics (TK) monitoring and gene expression analysis
The wild-type and Gstm1-null mice in the satellite groups of the 14-day repeated dose study were orally treated with DCNB for 14 days at dose levels of 0 and 300 mg/kg. Blood was sampled 2 hours after dosing on Days 1 and 14, based on the previous information in which maximum concentrations of plasma DCNB were exhibited around 2 hours after the DCNB treatment (Fujimoto et al., 2006) . Then, the blood samples were centrifuged at 10,000 rpm for 5 min at 4°C to obtain samples of the plasma and blood cells. The TK samples were stored in a freezer set at -80°C. The spleens of females were also stored in a freezer set at -80°C and used for microarray and quantitative RT-PCR analyses.
Hematological examination
On the day of autopsy, the animals were anesthetized with ether and blood samples were collected from the inferior vena cava. These samples were placed in blood sampling tubes (MICROTAINER:
Nippon Becton Dickinson Company, Ltd., Tokyo, Japan) coated with EDTA-2K. The samples for analysis, along with an automated blood cell counter, were mixed with equal volumes of physiological saline (Otsuka Pharmaceutical Industries, Tokyo, Japan). The red blood cell count (RBC) and reticulocyte count (RET) were determined using an ADVIA120 automated blood cell counter (Bayer This article has not been copyedited and formatted. The final version may differ from this version. Medical Ltd., Tokyo, Japan). Blood methemoglobin (MetHB) was determined by the spectrophotometric method with a 7011 clinical spectrophotometer (Hitachi, Ltd., Tokyo, Japan).
Pathological examination
Macroscopic observations of organs and tissues were performed in each study during the autopsy.
For the microscopic examinations, the organs and tissues were removed and then fixed in 10% neutral buffered formalin, embedded in paraffin, sectioned at a thickness of 2-3 µm and stained with hematoxylin and eosin (HE). The grading score of increased extramedullary hematopoiesis in the spleen was determined based on the area percentage of the hematopoietic cells within spleen sections.
The criteria of grading score were defined as follows. No change ( < 10 % increase) in area percentage of hematopoietic cells within spleen sections compared with the control was defined as grade 0. Slight increase (10-40 % increase), moderate increase (41-60 % increase) and marked increase ( > 60 % increase) were defined as grade 1, grade 2 and grade 3, respectively.
Microarray analysis
Microarray analysis was performed according to the Affymetrix standard protocol. Briefly, total RNA was isolated from the individual female mouse spleen, and the pooled RNA samples were prepared for both wild-type and Gstm1-null mice by mixing an equal amount of RNA samples within the groups. Five μ g of the pooled RNA was used for cDNA synthesis using a T7-(dT) 24 primer (GE Healthcare, Little Chalfont, Buckinghamshire, UK). A biotin-labeled cRNA mix was transcribed using BioArray High Yield RNA Transcription Labeling Kit (Enzo Diagnostics, Farmingdale, NY, USA). 
Microarray data analysis
Probe sets whose Change Call showed "NC" (Not Changed) and/or whose |Signal Log Ratio| values were lower than 0.6 were excluded from the analysis. In addition, probe sets whose sequences are not annotated with Entrez Gene ID were excluded from the data analysis as well. In the present study, we hypothesized that Gstm1-null mice-specific gene expression regulation might be associated with the marked increase in extramedullary hematopoiesis in the spleen of Gstm1-null mice. Accordingly, genes whose expression levels increased in the Gstm1-null mice (|expression ratio to control| > 1.4), but not in the wild-type mice (|expression ratio to control| < 1.4) following DCNB treatment were extracted in Table 3 . Genes whose increasing ratio between Gstm1-null and wild-type mice (Gstm1-null / Wild-type) exhibited values greater than 2.5 are listed in the table.
Quantitative RT-PCR
Expression levels of mouse matrix metallopeptidase 9 (Mmp9), chitinase 3-like 1 (Chi3l3), Biosystems PRISM 7000 Sequence Detection System using the following conditions: initial denaturation and enzyme activation for 10 min at 95°C, followed by 40 cycles of 95°C for 15 s and 60°C for 1 min. A dissociation protocol was performed to assess the specificity of the primers and the uniformity of the PCR generated products. Each plate contained duplicate standards of purified PCR products of known template concentrations covering eight orders of magnitude to interpolate relative template concentrations of the samples from the standard curves of log copy number versus the threshold cycle. The copy number of each unknown sample per gene was standardized to that of the Gapdh gene to control for differences in RNA loading, quality and cDNA synthesis. Primer sequences and amplicon sizes are shown in Table 1 . ethanol and centrifuged at 3000 rpm for 5 min at 4°C. To determine the concentration of DCNB, the supernatant was subjected to high-performance liquid chromatography (HPLC) system (Shimadzu Corporation, Kyoto, Japan) consisting of a system controller (SCL-10A), a pump (LC-10AD), an autosampler (SIL-10AXL), a column oven (CTO-10AC) and a UV detector (SPD-10A). The HPLC conditions for this analysis were as follows: the column was an L-column ODS (150 x 4.6 mm i.d.;
TK analysis for DCNB and its metabolite, M0 (methylsulfon-N-acetyl form of DCNB)
Chemicals Evaluation and Research Institute, Tokyo, Japan); the column temperature was 40°C; the mobile phase was water/acetonitrile/1M ammonium acetate at 55/45/1 (v/v/v); the flow rate was 1.0 ml/min; the injection volume was 10 µl and the UV detector wavelength was 270 nm.
Statistical analyses
The results are expressed as the mean ± standard deviation (S.D. 
Results
Single dose study of DCNB
The toxicological responses to DCNB in wild-type and Gstm1-null mice were examined in the single dose study. In the hematological examination, a remarkable increase in MetHB was observed in Gstm1-null mice, which was similar in both sexes (Fig. 1) . Although a statistically significant increase in MetHB was observed in the wild-type females given 1000 mg/kg, the magnitude of the increase was slight compared with Gstm1-null mice.
14-day repeated dose study of DCNB
Toxicological responses to DCNB in wild-type and Gstm1-null mice were examined in the 14-day repeated dose study. Three wild-type males given 600 mg/kg died on Days 8 and 10. One wild-type female given 600 mg/kg died on Day 5. Three Gstm1-null females given 600 mg/kg died on Days 4, 5 and 6. Although decreases in activity and fecal volume were observed in the dead animals, no pathological changes were observed in the results of the unscheduled autopsies (data not shown) and the cause of death could not be confirmed. In the hematological examination, a remarkable increase in MetHB was observed in both wild-type and Gstm1-null mice, which was similar in both sexes ( Fig.   2A ). On the other hand, a remarkable increase in RET was observed in the Gstm1-null mice (Fig. 2B) .
Although a statistically significant increase in RET was observed in the wild-type mice, the magnitude of the increase was slight compared with the Gstm1-null mice. A slight decrease in RBC was observed This article has not been copyedited and formatted. The final version may differ from this version. in wild-type males and Gstm1-null females (Fig. 2C ). In the relative organ weight, an increase in spleen weight was observed in the Gstm1-null mice (Fig. 3) . In the pathological examination conducted as an additional study, increased extramedullary hematopoiesis was observed in both strains with a higher grade score in the Gstm1-null mice (Table 2 ). Microarray analysis in the spleen demonstrated genes whose expression levels increased in the Gstm1-null mice (|expression ratio to control| > 1.4), but not in the wild-type mice (|expression ratio to control| < 1.4) following DCNB treatment. All the microarray data are presented as Supplementary Table S1 and are available at the publisher's website. Genes whose increasing ratio between Gstm1-null and wild-type mice (Gstm1-null / Wild-type) exhibited a greater value than 2.5 are listed in Table 3 . From these genes, the representative 5 genes which are related to hematopoiesis (i.e., Mmp9, Chi3l3, Trem3, Ms4a3 and Lcn2) were evaluated by quantitative RT-PCR. Quantitative RT-PCR showed exclusive up-regulation in Gstm1-null mice following DCNB treatment (Fig. 4) , consistent with the results of microarray analysis.
TK monitoring
TK monitoring in plasma and blood cells was performed in the wild-type and Gstm1-null mice in the satellite groups of the 14-day repeated dose study. DCNB concentrations in the Gstm1-null mice on Days 1 and 14 were higher than those in the wild-type mice in both plasma and blood cells (Fig. 5A and Fig. 5B ). There were no apparent changes in DCNB concentrations after repeated dosing for 14
This article has not been copyedited and formatted. The final version may differ from this version. days. DCNB concentrations in blood cells were higher than those in plasma and the ratio of blood cells/plasma was similar in both strains (Fig. 5C ). Although a statistically significant increase was observed in the wild-type females, the magnitude of the increase was slight. Plasma M0 concentrations on Days 1 and 14 in the Gstm1-null mice were lower than those in the wild-type mice (Fig. 5D ). M0
concentrations in blood cells were below the lower limit of quantitation in most of the samples and could not be evaluated appropriately.
This article has not been copyedited and formatted. The final version may differ from this version. 
Discussion
We investigated the effect of murine Gstm1 disruption on the toxicological response to DCNB, a specific substrate to Mu class GST, using Gstm1-null mice.
In the single dose study, a marked increase in blood MetHB was observed in the Gstm1-null mice, and the magnitude of the increase was greater than that of wild-type mice. Therefore, Gstm1-null mice were considered to be more predisposed to methemoglobinemia induced by a single dosing of DCNB and it is suggested that the effect of Gstm1 disruption was reflected in methemoglobinemia in the single dose study of DCNB. Since Gstm1-null mice showed markedly low GST activity to DCNB (Fujimoto et al., 2006) and higher exposure to DCNB in Gstm1-null mice was confirmed in TK monitoring, predisposition to methemoglobinemia observed in Gstm1-null mice in the single dose study is considered to be attributed to the higher exposure to DCNB.
In the 14-day repeated dose study, in contrast, a marked increase in blood MetHB was observed in both wild-type and Gstm1-null mice, and the magnitude of the increase was similar in both strains.
However, increases in blood RET, relative spleen weight and extramedullary hematopoiesis in the spleen were markedly observed in Gstm1-null mice. These changes were considered to be adaptive responses to methemoglobinemia, since it has been reported that repeated dose studies of typical compounds that cause methemoglobinemia, such as nitrobenzene (Cattley et al., 1994) , p-nitrochlorobenzene (Nair et al., 1986) and aniline (Hejtmancik et al., 2002) , showed similar responses in experimental animals. The increase in blood RET is compensatory hematopoiesis This article has not been copyedited and formatted. The final version may differ from this version. response to elevation of damaged erythrocytes, and the increase in relative spleen weight is attributed to sequestration of damaged erythrocytes and extramedullary hematopoiesis. In addition, these adaptive responses were not observed in the single dose study of DCNB and it has been reported that an increase in spleen weight was not observed 24 hours after dosing with aniline to rats (Kahn MF et al., 1997) . Therefore, it is suggested that the adaptive responses enhanced by the repeated dosing for 14 days in Gstm1-null mice attenuated the higher predisposition to methemoglobinemia in the single dose study. Additionally, a single dosing seems to be not enough to show sufficient adaptive responses to methemoglobinemia. To get an insight on the molecular mechanism of adaptive responses, microarray analysis was conducted in the spleen of females and revealed that a number of genes were up-regulated exclusively in Gstm1-null mice following DCNB treatment. Five hematopoiesis-related genes were subjected to quantitative RT-PCR analysis to confirm their up-regulation, which was observed exclusively in the Gstm1-null mice, namely, Mmp9, Chi3l3, Trem3, Ms4a3 and Lcn2. It has been reported that Mmp9 activation enhanced stem and progenitor cell recruitment, and was found to be an essential factor for hematopoiesis (Heissig et al., 2002) . The activation of Mmp9-mediated response is also suggested by the up-regulation of Chi3l3, which is a chitinase family protein reported to be a substrate of Mmp9 and expressed in macrophages (Greenlee et al., 2006) . Another macrophage-expressed gene Trem3, which functions as an activating receptor (Chung et al., 2002) , was also up-regulated in the Gstm1-null mice, suggesting that inflammatory cells were activated in the
Gstm1-null mice after DCNB treatment. In addition, Ms4a3 is expressed in hematopoietic tissues and
This article has not been copyedited and formatted. The final version may differ from this version. is tightly regulated during the differentiation of hematopoietic stem cells (Donato et al., 2002) . On the other hand, Lpn2, a suppressor of red blood cell production (Miharada et al., 2005) , was also found to be exclusively up-regulated in the Gstm1-null mice, which may be a feedback response against stimulated extramedullary hematopoiesis in the spleen. Collectively, splenic gene expression analysis in the repeated dose study of DCNB showed exclusive up-regulation of hematopoiesis-related genes in
Gstm1-null mice, supporting the increased extramedullary hematopoiesis in the spleen. However, several genes whose biological functions are not apparently associated with hematopoiesis were found to exhibit exclusive up-regulation in Gstm1-null mice after the DCNB treatment, such as Mmp8, Tm7sf3 and Spag5 by microarray analysis. Further investigation will be needed to clarify the biological and toxicological significance of these gene expression changes that were exaggerated by the disruption of Gstm1 gene following DCNB treatment. Regarding other parameters which changed in the 14-day repeated dose study, a slight decrease in RBC was observed in Gstm1-null females, but not in Gstm1-null males. Although it has been reported that typical compounds that cause methemoglobinemia were accompanied by a hemolytic anemia (Cattley et al., 1994; Nair et al., 1986; Hejtmancik et al., 2002) , not all compounds are hemolytic such as chlorpropham (Fujitani et al., 2000) and sodium nitrite (National Toxicology Program, 2001) . Therefore, it appears that methemoglobinemia induced by DCNB is not clearly associated with hemolytic anemia. In summary of the 14-day repeated dose study of DCNB, it is suggest that the effect of Gstm1 disruption was reflected in adaptive responses to methemoglobinemia. This fact indicates that enhanced adaptive This article has not been copyedited and formatted. The final version may differ from this version. responses might mask the toxicities and careful interpretation might be necessary to utilize genetically modified animals for the evaluation of toxicities.
In TK monitoring conducted in the satellite groups of the 14-day repeated dose study, DCNB concentrations on Days 1 and 14 in plasma and blood cells were higher in Gstm1-null mice than in wild-type mice. In addition, it appears that the movement of DCNB from plasma to blood cells and vice versa was not disturbed in Gstm1-null mice, since the ratio of blood cells/plasma was similar in both strains. Accordingly, the methemoglobinemia observed in the single dose study and the adaptive responses observed in the 14-day repeated dose study were considered to be based on a higher systemic exposure to DCNB in Gstm1-null mice. Although the metabolic pathway of DCNB has not yet been fully examined, it has been reported that glutathione conjugation by GST and the subsequent mercapturic acid formation were considered to be the main elimination pathway in the case of p-nitrochlorobenzene (Yoshida, 1994) . Therefore, it seems reasonable to consider that glutathione conjugation catalyzed by GSTM1 and subsequent mercapturic acid formation would also be the main elimination pathway in the case of DCNB. The previous report (Fujimoto et al., 2006) showed a lower plasma concentration of M0 in Gstm1-null mice than in wild-type mice. Additionally, a structural analysis of M0 revealed that the sulfur atom from glutathione was incorporated in M0, suggesting that M0 was produced after glutathione conjugation of DCNB. Moreover, the molecular weight of M0 was estimated to be 247 and this was smaller than the glutathione conjugate of DCNB, whose molecular weight was 462. Considering these facts, it is suggested that DCNB is metabolized to M0 via a This article has not been copyedited and formatted. The final version may differ from this version. mercapturic acid pathway and is eliminated into the bile or urine. In the present study, plasma M0 concentrations in Gstm1-null mice showed lower values than those of wild-type mice and the results of the previous study were reproduced.
In conclusion, Gstm1-null mice showed marked methemoglobinemia and adaptive responses in single and repeated dose studies of DCNB, respectively. These findings were considered to be based on the higher exposure to DCNB due to Gstm1 disruption. It is suggested that the effect of Gstm1 disruption was reflected in toxicological responses related to methemoglobinemia. This study showed an example of a new approach to utilize genetically modified animals for the evaluation of toxicities that depend on drug metabolism.
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